KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In Process
Ratios

CRISPR Therapeutics AG (CRSP) Receivables - Other (2016 - 2024)

CRISPR Therapeutics AG's Receivables - Other history spans 9 years, with the latest figure at $2.1 million for Q4 2024.

  • For Q4 2024, Receivables - Other fell 67.69% year-over-year to $2.1 million; the TTM value through Dec 2024 reached $2.1 million, down 67.69%, while the annual FY2024 figure was $2.1 million, 67.69% down from the prior year.
  • Receivables - Other for Q4 2024 was $2.1 million at CRISPR Therapeutics AG, down from $6.5 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $25.0 million in Q1 2020 and bottomed at $2.1 million in Q4 2024.
  • The 5-year median for Receivables - Other is $11.0 million (2020), against an average of $14.2 million.
  • The largest annual shift saw Receivables - Other soared 64002.56% in 2020 before it crashed 67.69% in 2024.
  • A 5-year view of Receivables - Other shows it stood at $10.7 million in 2020, then fell by 21.5% to $8.4 million in 2021, then soared by 33.33% to $11.2 million in 2022, then crashed by 41.96% to $6.5 million in 2023, then plummeted by 67.69% to $2.1 million in 2024.
  • Per Business Quant, the three most recent readings for CRSP's Receivables - Other are $2.1 million (Q4 2024), $6.5 million (Q4 2023), and $11.2 million (Q4 2022).